This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Solazyme And Dow Enter Into Contingent Global Commercial Offtake Agreement And Concurrently Sign Phase 2 Joint Development Agreement To Accelerate Commercialization Of Bio-based Dielectric Insulating Fluids

Solazyme, Inc. (NASDAQ: SZYM), a renewable oil and bioproducts company, and The Dow Chemical Company (NYSE: DOW), announced today that they have entered into a contingent offtake agreement in which Dow has agreed to purchase from Solazyme all of its requirements of non-vegetable microbe-based oils for use in dielectric fluid applications through 2015, contingent upon Solazyme’s ability to supply such oils within agreed specifications and certain terms and conditions of the sale. These new, renewable and biodegradable bio-based dielectric insulating fluids offer increased fire safety thanks to higher flash points and provide additional functionality that may improve the operating efficiency and extend the useful life of transformers.

Concurrently, Solazyme and Dow have entered into a Phase 2 Joint Development Agreement (JDA2), an exclusive, multi-year extension of the current joint-development agreement including accelerated commercialization timelines based on Solazyme’s rapid progress in the production of tailored algal oils. JDA2 enables additional application development work to be conducted by Dow, due to Solazyme’s accelerated ability to scale up their uniquely tailored algal oil feedstocks. Consumption of Solazyme’s algal oil feedstocks is expected to significantly exceed the minimum estimated volumes of 8.5 million gallons (29,000 metric tons) starting in the second half of 2013 and through 2015. The offtake agreement contemplates that final pricing for the oil will be linked to certain items including Solazyme’s sugar-based feedstock costs.

“Solazyme’s unique biotechnology-based oils platform has created a new market opportunity to develop and produce the next-generation of safe, renewable, dielectric insulating fluids that provide increased performance benefits,” said Jonathan Wolfson, CEO, Solazyme. “We have continued to reach technological advancements ahead of schedule with Dow, enabling us to further progress our commercial relationship.”

"Solazyme is a leading company in the industrial biotechnology space and its renewable oil technology platform provides a unique opportunity to significantly accelerate the development of next-generation, bio-based, non-vegetable dielectric insulating fluids,” said Tim Laughlin, General Manager, Dow Electrical & Telecommunications. "In the fast-growing space of bio-based dielectric insulating fluids, Solazyme’s tailored algal oils will serve as a technology platform for our continued efforts to bring innovative solutions to the power industry. Advanced field trials in transformers will be initiated to further prove the technology and value proposition of these new products in the near term. Based on the application work we have already completed to date, we are confident we are positioned to commercialize these oils in timelines consistent with Solazyme’s planned ability to manufacture the quantities we need.”

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,668.46 -211.90 -1.26%
S&P 500 1,944.34 -25.73 -1.31%
NASDAQ 4,389.9770 -72.9250 -1.63%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs